ConductScience.org, home

Library / Trial comparisons

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One AE Leading to Withdrawal

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 1000.000758wilsonClinicalTrials.gov
Risk in group 20.0009860.0004210.00231wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000986-0.00231-0.0000406newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 2loga group has no participants with the outcomeClinicalTrials.gov
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zeroClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Quadrivalent VLP Vaccine than on Placebo1,01043424,600from the risk difference intervalClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Quadrivalent VLP VaccineParticipants received one IM injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.05,064OG000ClinicalTrials.gov
Group 2PlaceboParticipants received one IM injection of 0.5 mL of placebo on Day 0.55,072OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With at Least One AE Leading to WithdrawalClinicalTrials.gov
Description
An AE or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. The number of participants with at least one adverse event leading to withdrawal was assessed.
ClinicalTrials.gov
Time frameDay 0 up to ~8 monthsClinicalTrials.gov
PopulationSASClinicalTrials.gov

Trial 8

FieldValueSource
TitleEfficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsClinicalTrials.gov
NCT numberNCT03301051ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsVirus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, InfluenzaClinicalTrials.gov
InterventionsQuadrivalent VLP Vaccine, PlaceboClinicalTrials.gov
Lead sponsorMedicagoClinicalTrials.gov
Results first posted2023-08-14ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT03301051?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.